Evidence map›Paper›PMID 42327041›Full record

ArticlebioRxiv : the preprint server for biology2026

Mapping the genetic landscape of the DNA damage response with Cas12a-based combinatorial knockout screens.

Samuel B Hayward, Alina Vaitsiankova, Tomas Lama-Diaz, Juihsuan Chou, Angelo Taglialatela, Jen-Wei Huang, Yodharaudshani Wijesekarahanthi, Joshua R Heyza, Giuseppe Leuzzi, Chuanyuan Chen and 13 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Samuel B HaywardDepartment of Genetics and Development, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY, USA.
Alina VaitsiankovaDepartment of Genetics and Development, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY, USA.
Tomas Lama-DiazDepartment of Genetics and Development, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY, USA.
Juihsuan ChouDepartment of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Angelo TaglialatelaDepartment of Genetics and Development, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY, USA.
Jen-Wei HuangDepartment of Genetics and Development, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY, USA.
Yodharaudshani WijesekarahanthiIFOM ETS - The AIRC Institute of Molecular Oncology, Italy.
Joshua R HeyzaInstitute for Quantitative Health Science and Engineering, Michigan State University, East Lansing, MI, USA.
Giuseppe LeuzziDepartment of Genetics and Development, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY, USA.
Chuanyuan ChenLaboratory of Genome Integrity, National Cancer Institute, NIH, Bethesda, MD, USA.
Nancy WongLaboratory of Genome Integrity, National Cancer Institute, NIH, Bethesda, MD, USA.
Tenzin LhakhangProgram for Mathematical Genomics, Department of Systems Biology, Columbia University, New York, NY, USA.
Xi FuProgram for Mathematical Genomics, Department of Systems Biology, Columbia University, New York, NY, USA.
Alejandro L BuendiaProgram for Mathematical Genomics, Department of Systems Biology, Columbia University, New York, NY, USA.
Veronica GheorgheDepartment of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Nazanin Esmaeili AnvarDepartment of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jens C SchmidtInstitute for Quantitative Health Science and Engineering, Michigan State University, East Lansing, MI, USA.
Andre NussenzweigLaboratory of Genome Integrity, National Cancer Institute, NIH, Bethesda, MD, USA.
Raul RabadanProgram for Mathematical Genomics, Department of Systems Biology, Columbia University, New York, NY, USA.
Vincenzo CostanzoIFOM ETS - The AIRC Institute of Molecular Oncology, Italy.
Raphaël GuéroisUniversité Paris-Saclay, CEA, CNRS, Institute for Integrative Biology of the Cell (I2BC), Gifsur-Yvette, France.
Traver HartDepartment of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Alberto CicciaDepartment of Genetics and Development, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY, USA.

Funding

Tumor Biology and Microenvironment ProgramP30CA013696 · NCI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI Parisa Tehranifar · 1985 to 2026
$115.3M
The Role of CTIP in Lymphocyte Development and LymphomagenesisP01CA174653 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI RABADAN, RAUL · 2014 to 2024
$17.6M
NRSA Training CoreTL1TR001875 · NCATS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI SPANN, MARISA N, TAYLOR, JACQUELYN Y · 2016 to 2025
$8.9M
Replication fork remodeling and genomic stabilityR01CA197774 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Alberto Ciccia · 2016 to 2026
$4.2M
Identifying and targeting collateral lethal vulnerabilities in cancersU01CA275886 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI RONALD ANTHONY DEPINHO, Traver Hart · 2023 to 2026
$3.9M
High-content microscopy platform for multiplex perturbation/multiplex readout studiesR35GM130119 · NIGMS · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Traver Hart · 2018 to 2026
$3.9M
Characterization of the functions of the DNA translocase SMARCAL1 in anti-tumor immunityR01CA304254 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Alberto Ciccia · 2026 to 2026
$630k
NCATS NIH HHS TL1 TR001875NCI NIH HHS P01 CA174653NCI NIH HHS P30 CA013696NCI NIH HHS R01 CA197774NCI NIH HHS R01 CA304254NCI NIH HHS U01 CA275886NIGMS NIH HHS R35 GM130119
6 · The paper itself

Abstract

The DNA damage response (DDR) is a complex network of cellular pathways that ensures the faithful maintenance of our genomes upon a wide array of genomic insults. To elucidate the functional architecture of this network, we conducted unbiased genetic interaction screens using the Cas12a genome editor to disrupt 233 DDR genes frequently mutated in cancer and other genetic diseases, either individually or in pairwise combinations. This approach enabled us to assess the phenotypic effects induced by the disruption of >27,000 DDR gene pair combinations under unperturbed cell growth conditions. From this analysis, we identified over 750 high-confidence positive (buffering) or negative (synthetic lethal/sick) gene-gene interactions, along with multiple connections between previously unlinked DDR pathways and modules, allowing us to define novel aspects of the cellular response to spontaneous, DNA replication-associated DNA damage. Among the identified genetic interactions, we uncovered profound synthetic lethal interactions between genes encoding 1) the translesion polymerase REV1-Pol ζ complex and the MCM8-MCM9-HROB DNA helicase complex; 2) Fanconi Anemia (FA) proteins and the mitotic DNA repair factors GEN1, CIP2A, and RHINO; and 3) the DNA translocase SMARCAL1 and components of the FANCM complex, suggesting novel opportunities for targeted therapies in tumors carrying mutations in these genes. Additionally, we identified robust suppressor interactions between the

Identifiers

PMID42327041
PMCPMC13278138

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.